Results: Five patients with UELS were identified. Patients initially presented with fever, abdominal pain, or nausea. Ages ranged from 10 to 19 years old (median age 13 y old), and there was a 4:1 male-tofemale predominance. Tumor size ranged from 6 to 22 cm in largest diameter. One patient presented with metastatic disease to the lungs and heart and 1 patient recurred 2 years from diagnosis with bilateral paraspinal masses. Treatment included local control surgery with neoadjuvant and adjuvant chemotherapy with an anthracycline/ alkylating agent combination. One patient with recurrent and refractory disease achieved local control with an orthotopic liver transplantation (OLT). Metastatic disease was controlled with surgery and radiation therapy. 18-Fluorodeoxyglucose PET/CT was a useful imaging tool for judging response to therapy with complete loss of metabolic activity in tumor after neoadjuvant chemotherapy in 2 representative cases. Although follow-up is short for some patients, overall survival in these 5 patients was 100% with follow-up ranging from 21 to 68 months. Disease-free survival ranged from 8 to 46 months with no patients with residual disease.
Conclusions: UELS is an aggressive high-grade primary liver sarcoma with high metastatic potential. This report represents one of the largest single-institution studies of UELS. Using multimodality therapy, patients have achieved 100% overall survival even in the setting of extensive disease, metastases, and recurrence. In cases of unresectable primary tumor or recurrent and refractory disease isolated to the liver, OLT is a potential therapeutic option. We report success with adjuvant chemotherapy and complete surgical resection with OLT as an alternative in unresectable or refractory cases. We also suggest a possible utility of PET/CT in monitoring treatment response in this disease. U ndifferentiated embryonal liver sarcoma (UELS) is a rare malignant liver tumor of childhood making up 9% to 15% of all hepatic malignancies. 1 Diagnosis is usually made between 6 and 10 years of age and typical presenting signs and symptoms include nausea, anorexia, right upper quadrant mass, abdominal pain, and fever. Imaging typically reveals a large hepatic mass in the right lobe more often than the left lobe, made up of both cystic and solid components, and occasionally involving the portal system making them notoriously difficult to resect. 2 Newer studies suggest an older age distribution with average age of presentation being at 10.5 years of age. 1 Histology in the majority of cases contains spindle or stellate cells, pleomorphic and prominent eosinophilia, with variable immunohistochemistry staining. 1, 3, 4 Serum a-fetoprotein is normal. Negative myogenin staining typically differentiates UELS from rhabdomyosarcomas. 5 Some have argued that UELS is on a spectrum with mesenchymal hamartoma. 6 There have also been reports of association with p53 mutations. 7 UELS has high metastatic potential primarily to lung and lymph nodes. Recurrences are mostly locoregional in nature, but they have been reported in the lungs, bone, and brain. 3 UELS are aggressive sarcomas and historically carried a poor prognosis before development of multimodal therapy with reported survival rates of <37.5%. 4, 8 Previous studies have shown success with combined surgical and adjuvant chemotherapy regimens based on treatment of other childhood soft tissue and hepatic malignancies. [8] [9] [10] [11] There have been several case reports of success with liver transplantation in refractory or unresectable cases. 12, 13 However, there is no standard therapeutic approach to these malignancies.
We present 5 cases of UELS in one of the largest case series from a single institution treated successfully with combined surgical and adjuvant chemotherapy protocols. We also report successful outcome of total hepatectomy and orthotopic liver transplantation (OLT) in a patient with locally recurrent/refractory disease not amenable to surgical resection. We report success with adjuvant chemotherapy with an ifosfamide-based and doxorubicin-based regimen combined with complete surgical resection as standard of care for treatment of UELS with total hepatectomy and OLT as an alternative in unresectable or refractory cases.
METHODS
This is an Institutional Review Board (IRB)-approved [University of California Los Angeles (UCLA) IRB approval #11-001743] retrospective review of 5 cases of UELS in patients younger than 21 years of age seen at UCLA identified in the UCLA Sarcoma and Liver Transplant Databases. Chart review was conducted searching for multiple parameters: age, sex, ethnicity, signs and symptoms at presentation, date and age of diagnosis, location of tumor, presence and location of metastases, imaging results, histology and pathology reports, size of tumor, chemotherapy regimen, use of any salvage chemotherapy, use of surgery, liver transplantation, recurrence and site of recurrence, morbidity and mortality, and survival in months from diagnosis and months of disease-free survival. Patients were assigned letters; medical record numbers, names, and other identifying data were removed before data analysis. Results were documented as a descriptive analysis of a case series. Patient C was treated elsewhere but was included in our study, because he received OLT at our institution and was followed here subsequently.
RESULTS

Patient Characteristics
The age of patients ranged from 10 to 19 years of age, median 13 years, an older age range than previously reported. 2 There was a 4:1 male-to-female ratio. There was no predominance of ethnicity. The symptoms at presentation included fever, abdominal pain, abdominal mass, nausea and vomiting, fatigue, constipation, abdominal asymmetry, and acute abdomen. The most common presenting symptom was right upper quadrant or nonspecific abdominal pain.
Tumor Characteristics
Tumor size ranged from 6 to 22.6 cm in largest diameter. Four of 5 tumors were located in the right hepatic lobe. Patient C presented to UCLA at the time of recurrence after being treated in a foreign country, and a primary hepatic lobe site of tumor was not specified. Patient E's primary tumor was located in the right hepatic lobe and extended into the inferior vena cava and right atrium. Two tumors were noted to be multiloculated and cystic on initial imaging studies. Patient D had an exophytic mass extending from the right lobe of the liver. Histology revealed uniformly pleomorphic spindle and stellate cells with occasional bizarre giant cells. Immunohistochemistry revealed universally negative myogenin and desmin staining and variable a-1 antitrypsin staining. One patient presented with pulmonary metastatic disease and 1 had distant recurrence of disease with pulmonary and paraspinal metastases at 2 years from completion of therapy.
Treatment and Outcome
Surgical resection and adjuvant chemotherapy formed the basis of treatment for the 5 patients. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , and 15 of 6 cycles of 28 days. Patient C received salvage chemotherapy consisting of ifosfamide, etoposide, and carboplatin for 2 cycles followed by another 2 cycles adjuvantly after liver transplantation with ifosfamide and carboplatin at an outside hospital (dosing information was not available). Both patients with metastatic disease received local radiation (6000 cGy) to the sites of metastatic disease. Patient B received 6000 cGy of radiation to pulmonary and paraspinal metastases, and patient E received 6000 cGy of radiation to pulmonary metastases. Patient E had extension of his tumor into the inferior vena cava but after chemotherapy repeat scans revealed no evidence of further disease with minimal scar tissue. He was placed on Arixtra for 4 months after chemotherapy. He has now been disease free for 8 months (Table 1) .
Patient B had a regional recurrence in the paraspinal area posterior to the liver, and patient C experienced a local recurrence of the tumor at the primary site. Patient C went on to receive a total hepatectomy and OLT for refractory disease. Overall, multimodal therapy was well tolerated. Patient B had a pulmonary embolism after resection of the paraspinal recurrence.
Baseline 18-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) in patients D and E showed that UELS is very 18 F-FDG avid. 18 F-FDG PET/CT performed after 2 cycles of neoadjuvant chemotherapy predicted response to chemotherapy with a significant decrease in 18 F-FDG uptake (Fig. 1A) . SUV max in patient D's tumor decreased from 9.6 to 1.5 after 2 cycles of neoadjuvant chemotherapy. SUV max in patient E's tumor decreased from 9.9 to 2.9 between February 11, 2011 and March 24, 2011 after 2 cycles of chemotherapy. Lung lesions also demonstrate decrease from an average SUV max of 10.3 to 1.3 with complete resolution in 2 lesions. Tumors were highly sensitive to neoadjuvant ifosfamide/doxorubicin chemotherapy showing both metabolic response and response by RECIST criteria on 18 F-FDG PET/CT as well as >90% pathologic necrosis on histopathologic analysis after resection. Disease-free survival ranged from 8 to 46 months with a mean of 30.2 months. Overall survival ranged from 21 to 68 months with a mean of 43 months. As of time of submission, all patients are alive, well, and disease free. No patients are currently receiving salvage chemotherapy for recurrent and/or metastatic disease.
DISCUSSION
Malignant liver tumors make up a little over 1% of pediatric malignancies, the most common of which is hepatoblastoma as opposed to hepatocellular carcinoma seen mostly commonly in adults. 19 Two thirds of all liver lesions are malignant, and overall there are 100 to 150 new cases of pediatric liver malignancies per year in the United States. 20, 21 Other less common pediatric liver malignancies include sarcomas, such as rhabdomyosarcoma and UELSs, as well as hepatocellular carcinoma. Neuroblastoma is the most common malignancy to metastasize to the liver followed by leukemia, lymphoma, and Wilms tumor.
The clinical differentiation of rhabdomyosarcoma and UELS can be difficult. Rhabdomyosarcoma usually occurs in children younger than 5 years and arises from the biliary ducts. These tumors account for 0.8% to 1% of pediatric liver malignancies. In contrast, UELS occurs more commonly in the 6-to 10-year age group arising within the liver itself. Jaundice is not typically present at diagnosis, whereas this is a common finding in rhabdomyosarcoma because of the biliary location. UELS accounts for 10% to 15% of pediatric liver malignancies. Unlike, hepatoblastoma and hepatocellular carcinoma, UELS is not associated with elevated a-fetoprotein. Also, it confers a much poorer prognosis historically than the approximately 85% 5-year survival rates seen with multimodal therapy for early-stage hepatoblastoma and liver biliary rhabdomyosarcoma.
Although hepatoblastoma and rhabdomyosarcoma are associated with heritable factors, such as, BeckwithWiedemann syndrome and familial adenomatous polyposis, and predisposing factors of low birth weight, there are no predisposing factors for the development of UELS. There are reports of germline p53 mutations in several patients; so, a careful genetic and family history should be obtained along with counseling for p53 testing. 22 Furthermore, mutations in the p53 gene have been shown within the UELS tumors themselves, supporting a role for p53 in UELS carcinogenesis.
Currently, CT and magnetic resonance imaging are the imaging modalities used to evaluate UELS tumors at presentation and after resection. Increasing evidence in pediatric and adult bone and soft tissue sarcomas suggests a role for 18 F-FDG PET/CT in staging evaluation, response to therapy, and surveillance of recurrence. [23] [24] [25] Two patients in this study demonstrated the utility of 18 F-FDG PET/CT as a modality for monitoring treatment response. Both patients had complete resolution of metabolic activity in the tumor after adjuvant chemotherapy. 18 F-FDG PET/ CT was very useful for monitoring treatment response in these patients and response to therapy by decreased PET/ CT SUV correlated with response to therapy by pathologic necrosis. However, attention must be paid to the use of pediatric imaging protocols to reduce radiation dosage and to overall cumulative radiation exposure.
In the treatment of UELS, complete surgical resection with negative margins is frequently difficult to achieve when the tumor is situated in close proximity to the major hepatic vessels (portal vein, hepatic vein, and hepatic artery). OLT has been successful as a definitive therapy for unresectable UELS refractory to chemotherapy or in recurrent cases. In 1 case of recurrent and refractory UELS, we have shown successful liver transplantation now disease free for 37 months with overall survival of 61 months since diagnosis. This is important as organ transplantation is not often considered as there is theoretical risk of primary malignancy recurrence with long-term immunosuppression, and transplant for salvage therapy is typically frowned upon because of inherent morbidity/mortality and the dearth of this valuable resource. However, for these "unresectable" cases of UELS, complete hepatectomy and OLT is the only means to achieve successful "local" control, a basic tenet in sarcoma therapy. In adult hepatocellular carcinoma, recent studies have shown large success with salvage transplantation and similar results to primary transplantation. 23, 24, 26 Although clearly speculative, we suggest that consideration for OLT in the UELS salvage setting be given to those patients who have disease that is chemoresponsive and do A recent study demonstrated similar results with 5 patients from a single institution treated with a uniform treatment approach that includes resection with neoadjuvant chemotherapy and radiation when indicated. 24 The authors of this study suggest that chemotherapy with vincristine, actinomycin, and cyclophosphamide along with surgical resection are sufficient for high cure rates in UELS without the addition of anthracyclines, topoisomerase inhibitors, or platinum compounds. The authors report a median survival rate of 53 months among their patients using this uniform approach. Our study differs in the age of patients (range of 4 to 13 y in recent study vs. 10 to 19 y in our study). The chemotherapeutic regimen was also different as our study used a soft tissue sarcoma anthracycline/ alkylating agent backbone regimen of ifosfamide and doxorubicin. Our study suggests similar findings of successful use of multimodal therapy including complete resection when possible, neoadjuvant chemotherapy and radiation to metastatic sites when indicated for patients diagnosed with pediatric UELS, and use of salvage chemotherapy in refractory or recurrent cases.
This case series further elicits descriptive data about UELS and suggests a model for histology-specific standardized multimodal therapy.
CONCLUSIONS
UELSs are rare and aggressive malignancies of children, adolescents, and young adults that have no standardized therapeutic approach other than achieving local control with attempt at complete surgical resection. Treatment modalities have been based on small case series in the literature. Early success has been shown in dual therapy with adjuvant chemotherapy and surgical resection. [8] [9] [10] [11] Chemotherapy regimens are based on known protocols for childhood sarcomas and liver malignancies. 8 In cases where the tumor is unresectable at diagnosis, prognosis is usually poor. 4, 8 Our study adds to the growing body of knowledge 18 F-FDG activity corresponding to the enhancing portions of the large multiseptated masses in the right hepatic lobe, predominantly along the posteromedial margins of the masses. The nonenhancing portions of the masses do not demonstrate significant metabolic activity, suggestive of central necrosis. There are innumerable large and small foci of intense metabolic activity within the bilateral lungs, corresponding to the solid enhancing pulmonary masses seen on CT. Prevascular and subcarinal mediastinal lymph nodes also demonstrate intense metabolic activity. Also, there are a few nonenhancing low-density hilar masses, predominantly on the right showing significant metabolic activity. B, Patient E after adjuvant chemotherapy PET/CT showed that pulmonary nodules within the lungs have dramatically decreased in size, number, and 18 F-FDG activity. There is some mild uptake within scattered pulmonary nodules of bilateral lower lobes. No focus of abnormal metabolic activity in the cervical, supraclavicular, mediastinal, axillary, retroperitoneal, or inguinal nodal regions. Hypodense lesions in the liver demonstrate much less 18 F-FDG activity than on prior study with only a mild focus of residual activity in the medial aspect of the largest hypodense lesion.
surrounding success of using chemotherapy regimens based on other childhood sarcomas and liver malignancies combined with surgical resection in these patients. 1, [3] [4] [5] [6] [7] [8] Our case series also adds cases of metastatic and recurrent tumors successfully treated with current chemotherapy regimens and, in a single refractory case, utility of OLT. We report success with surgical resection and adjuvant chemotherapy as the standard of care at our institution with liver transplantation as an option for unresectable and/or refractory cases. Finally, we show utility of 18 F-FDG PET/CT as a useful modality for monitoring disease progression and treatment response.
